Sacituzumab Tirumotecan in Participants With Locally Advanced or Metastatic Thymic Carcinoma

The goal of this clinical trial is to learn if drug Sac-TMT works to treat Thymic Carcinoma. It will also learn about the safety of Sac-TMT. The main questions it aims to answer are: * How effective is drug Sac-TMT in treating Thymic Carcinoma? * What adverse events (AEs) do participants have when taking drug Sac-TMT? Participants will: * Progress after at least one platinum-based chemotherapy treatment. * Take drug Sac-TMT every 2 weeks. * Take tumor response assessments every 6 weeks.

NCT Number	NCT07324629
Lead Sponsor	Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Conditions	Thymic Carcinoma
Enrollment	30 participants
Start Date	2026-03-13
Primary Completion	2028-04 (estimated)
Study Completion	2028-10 (estimated)
Updated on ClinicalTrials.gov	2026-08-12